Health Robotics' Releases i.v.STATION's 63% Annual Savings vs. PharMedium, or a 5-Month ROI on Just 4 APIs

Published: Sep 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOZEN, Sud-Tirol, Italy, September 9, 2013 /PRNewswire/ --

Health Robotics recently announced that Mercy Medical Center in Cedar Rapids released to Health Robotics' User Group an ROI study revealing 63% annual savings [or $313,918] as a result of insourcing just 4 active pharmaceutical ingredients (APIs) for sterile compounding patient doses on the i.v.STATION Robot [at an insourced cost of $184,988), compared to Mercy Medical Center's prior equivalent annual expense with PharMedium Services of $498,886 for the equivalent doses of these 4 APIs. i.v.STATION utilized standard BD syringes and Hospira IV Bags, with drug vials for Zosyn [Pfizer], Vancomycin [Pfizer, APP, and Hospira], Cefazolin [Sandoz and APP], and Heparin [APP, Sagent, and Hospira].

Amy Cobb, Mercy Medical Center's Director of Pharmacy Operations stated: "Our single i.v.STATION Robot prepared Zosyn powder reconstitutions and dilutions at an insourced cost of $122,888, compared to the equivalent annual PharMedium expense of $241,835, saving Mercy a total of $118,947 on a single API for 50 and 100ml Bags. At the same time, i.v.STATION also prepared Heparin dilutions at an internal annual cost of $22,440 for 5ml syringes compared to the equivalent annual PharMedium outlay of $113,220, saving Mercy a total of $90,780 on a single API."

Gaspar DeViedma, Health Robotics' Executive Vice President stated: "This represents a record 5-month payback for i.v.STATION, while 50+ outsourcing compounding centers [including 4 PharMedium locations in Memphis, Edison, Sugarland, and Cleveland] have been issued Forms 483 by the FDA for quality events during 2013 inspections. If this ROI and the tragic NECC meningitis events from 2012 do not make the case for Sterile Compounding Insourcing at hospital pharmacies with the i.v.STATION Robot, then I really wonder what ever will."

Ms. Cobb continued: "As far as Vancomycin, the same i.v.STATION Robot also prepared powder reconstitutions and dilutions on D5W, SWFI, and NS at an insourced cost of $22,500 compared to the equivalent annual PharMedium outlay of $106,165, saving Mercy a total of $83,665 on a single API for BD 20ml syringes and 100, 250 and 500ml Bags. Finally, the study showed that for Cefazolin, i.v.STATION additionally prepared powder reconstitutions and dilutions on D5W and NS at an internal cost of $17,160 compared to the equivalent annual PharMedium expense of $37,686, saving Mercy Medical Center a total of $20,526 on a single API for BD 20ml syringes and 50 and 100ml Bags."

About Health Robotics:

Founded in 2006 and now reaching 80% total IV Robots market share in the world [including over 90% the Oncology Robots global market], Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing almost 500 hospital installations in 5 continents with the only fully-integrated Robotics-based technology, IV Workflow, and manual compounding software automation solutions. Health Robotics' second generation products [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women’s Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6. , Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1., Comparing the upper limb disorder risks associated with manual and automated cytotoxic compounding. McLeod, Zochowska, Leonard, Crow, Jacklin, Dean, Franklin. Imperial College Healthcare NHS Trust. European Journal of Hospital Pharmacy April 2012.] to greatly contribute to ease hospitals' growing pressures to improve patient safety1, increase throughput, and contain costs1, 3. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug1 and diluent1 exchange errors, improve drug potency2, decrease other medical mistakes and sterility risks, work more efficiently1, 3, reduce waste and controlled substances' diversion, reduce pharmacy technician upper-limb injuries3, and diminish the gap between rising patient volume/acuity and scarce nursing and pharmacy staff.

For more information, please visit:

Help employers find you! Check out all the jobs and post your resume.

Back to news